



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Cheng Hwang et al.

Art Unit : 1615

Serial No.: 10/721,118

Examiner:

Filed

: November 25, 2003

Title

: REDUCTION OF HAIR GROWTH

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the attached form PTO-1449.

This statement is being filed before the receipt of a first Office action on the merits.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: April 20, 2004

Robert C. Nabinger Reg. No. 33,431

Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110-2804 Telephone: (617) 542-5070

Facsimile: (617) 542-8906

20830111.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit

Signature

Sherry L. Hunt

Typed or Printed Name of Person Signing Certificate

Substitute

PTO-1449

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 00216-654001

Applicant

Application No. 10/721,118

Information Disclosure Statement by Applicant (Use several sheets if necessary)

Cheng Hwang et al.

Filing Date

(37 CFR §1.98(b))

Group Art Unit November 25, 2003 1615

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2002/0052416 A1	05/02/02	Michelet et al.			
	AB	2002/0052414 A1	05/02/02	Bernard et al.			
	AC	2002/0045659 A1	04/18/02	Michelet et al.			
	AD	2002/0044953 A1	04/18/02	Michelet et al.			
	AE	6,369,098	04/09/02	Pershadsingh et al.			
	AF	2002/0019338 A1	02/14/02	Hebert			
	AG	6,299,865 B1	10/09/01	Styczynski et al.			
	AH	6,284,234	09/07/01	Niemiec et al.			
	AI	6,248,751 B1	06/19/01	Ahluwalia et al.			
	AJ	6,239,170 B1	05/29/01	Ahluwalia et al.			
	AK	6,235,737 B1	05/22/01	Styczynski et al.			
	AL	6,218,435 B1	04/17/01	Henry et al.		-	
	AM	6,121,269	09/19/00	Henry et al.			
	AN	6,093,748	07/25/00	Ahluwalia et al.			
	AO	6,060,471	05/09/00	Styczynski et al.			
	AP	6,037,326	03/14/00	Styczynski et al.			
	AQ	6,020,006	02/01/00	Styczynski et al.			
	AR	5,972,944	10/26/99	Antonucci et al.			-
	AS	5,962,466	10/05/99	Styczynski et al.			
<u> </u>	AT	5,958,946	09/28/99	Styczynski et al.			
	AU	5,939,458	08/17/99	Henry et al.			
	AV	5,908,867	06/01/99	Henry et al.			
	AW	5,866,595	02/02/99	Pershadsingh et al.			
	AX	5,840,752	11/24/98	Henry et al.			
	AY	5,824,694	10/20/98	Kurtz et al.			
	AZ	5,824,665	10/20/98	Henry et al.			
	AAA	5,776,442	07/07/98	Ahluwalia			

Examiner Signature	Date Considered
	<u> </u>
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include convert this form with

next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00216-654001	Application No. 10/721,118	
	closure Statement	Applicant Cheng Hwang et al.		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date November 25, 2003	Group Art Unit 1615	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	BA	5,728,736	03/07/98	Shander et al.			
	BB	5,700,835	12/23/97	Dean et al.			
	BC	5,674,477	10/07/97	Ahluwalia			
	BD	5,652,273	07/29/97	Henry et al.			
	BE	5,648,394	07/15/97	Boxall et al.			
	BF	5,645,825	07/08/97	Hillebrand et al.			
	BG	5,554,608	09/10/96	Ahluwalia et al.			
	ВН	5,474,763	12/12/95	Shander et al.			
	BI	5,468,476	11/31/95	Ahluwalia et al.			
	BJ	5,455,234	10/03/95	Ahluwalia et al.			
	BK	5,444,090	08/22/95	Ahluwalia			
	BL	5,411,991	05/02/95	Shander et al.		,	
	BM	5,364,885	11/15/94	Ahluwalia et al.		- 110	
	BN	5,362,748	11/08/94	Schwen et al.			
	ВО	5,328,686	07/12/94	Shander et al.			
	BP	5,300,284	04/05/94	Wiechers et al.			
	BQ	5,271,942	12/21/93	Heverhagen			
	BR	5,189,212	02/23/93	Ruenitz			
	BS	5,143,925	09/01/92	Shander et al.		-	
	BT	5,132,293	07/21/92	Shander et al.			
	BU	5,096,911	03/17/92	Ahluwalia et al.		•	
	BV	5,095,007	03/10/92	Ahluwalia			
	BW	4,935,231	06/19/90	Pigiet			
	BX	4,885,289	12/05/89	Breuer et al.			
	BY	4,720,489	01/19/88	Shander			
	BZ	4,562,204	12/31/85	Wakatsuka et al.			
	BAA	4,517,175	05/14/85	Iwabuchi et al.			

Examiner Signature	, Da	ate Considered	
	•		
EYAMINED: Initials citation considered Draw I	ing through citation if not in	conformance and not considered. Include convent this fo	man sedible

EXAMINER: Initials citation consinext communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00216-654001	Application No. 10/721,118	
	closure Statement oplicant	Applicant Cheng Hwang et al.		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date November 25, 2003	Group Art Unit 1615	

	U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate	
	CA	4,508,714	04/02/85	Cecic et al.				
	СВ	4,370,315	01/25/83	Greff et al.				
	CC	4,269,831	05/26/81	Ferrari et al.				
	CD	4,203,924	05/20/80	Nelson				
	CE	4,201,873	05/06/80	Peterson				
	CF	4,191,775	03/04/80	Glen				
	CG	4,161,540	07/17/79	Neri et al.			,	
	СН	4,139,638	02/13/79	Neri et al.				
	CI	4,039,669	08/02/77	Beyler et al.				
	CJ	3,426,137	02/04/69	Philpitt et al.				
	CK	3,878,239	04/15/75	Hyashi et al.				
	CL	3,426,137	02/04/69	Philipitt et al.				

	Foreig	n Patent Docum	ents or Publi	shed Foreign F	Patent A	Application	าร	
Examiner	Desig.	Document	Publication	Country or				lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	CM-	WO 03/020209 A2	03/13/03	PCT				
	CN	WO 02/13812 A1	02/21/02	PCT				
	СО	WO 01/74315 A2	10/11/01	PCT				
	СР	WO 01/74314 A2	10/11/01	PCT				
	CQ	WO 01/74313 A2	10/11/01	PCT				-
	CR	WO 01/74307 A2	10/11/01	PCT				
	CS	WO 01/62237 A3	08/30/01	PCT				
	CT	WO 01/54654 A2	08/02/01	PCT				
	CU	WO 00/62766	10/26/00	PCT				
	CV	WO 00/50002	08/31/00	PCT				
	CW	WO 00/48559	08/24/00	PCT				
	CX	WO 98/02134	01/22/98	PCT				

Examiner Signature

Date Considered

EXAMINER: Initials sitation considered Drawling through sitation if not in conformation and an advantage of the few sites in conformations and an advantage of the few sites in conformations and an advantage of the few sites in conformations and an advantage of the few sites in conformations and an advantage of the few sites in conformations and advantage of the few sites in conformations are advantage of the few sites in conformations and advantage of the few sites in conformations and advantage of the few sites in

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00216-654001	Application No. 10/721,118	
1	closure Statement oplicant	Applicant Cheng Hwang et al.		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date November 25, 2003	Group Art Unit 1615	

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or			Trans	lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	DA	EP 0 413 528	11/15/95	EPO				
	DB	WO 94/21216	09/29/94	PCT				
	DC	0 532 219 A2	09/02/92	EPO				
	DD	WO 92/10164	06/25/92	PCT				
	DE	EP 0 098 141	06/29/84	ЕРО				
	DF	EP 0 097 023	12/28/83	ЕРО				
	DG	1 458 349	1215/76	London				

	Other Documents (include Author, Title, Date, and Place of Publication)						
Examiner Initial	Desig. ID	Document					
	DH	Malholtra et al., "Percutaneous Absorption and Pharmacokinetics of Eflornithine HCl 13.9% Cream in Women with Unwanted Facial Hair", Journal of Clinical Pharmacology, Vol. 41, No. 9, pp. 972-978, September 2001					
	DI	Beisson et al., "Use of the Tape Stripping Technique for Directly Quantifying Esterase Activities in Human Stratum Corneum", Analytical Biochemistry, Vol. 290, No. 2, pp. 179-185, March 15, 2001					
	DJ	Moretti et al., "Oncostatic Activity of a Thiazolidinedione Derivative on Human Androgen- Dependent Prostate Cancer Cells", Int. J. Cancer: 92, 733-737 (2001)					
	DK	Breyer et al., "Prostanoid Receptors: Subtypes and Signaling", Annu. Rev. Pharmacol. Toxicol., 41:661-90, 2001					
	DL	Ellis, et al., "Troglitazone Improves Psoriasis and Normalizes Models of Proliferative Skin Disease", Arch. Dermatol, 136, p. 609-616, May 2000					
	DM	Corton et al., "Central Role of Peroxisome Proliferator-Activated Receptors in the Actions of Peroxisome Proliferators, Annu. Rev. Pharmacol. Toxicol., 40:491-518, 2000					
	DN	Kersten et al., "Peroxisome Proliferator Activated Receptor Agonists", New Approaches to Drug Development, pp. 141-151, 2000					
	DO	Balfour et al., "Rosiglitazone", Drugs, 57 (6) pp. 922-930, June 2000					
	DP	Lawrence et al., "Pioglitazone", IJCP, Vol. 54, No. 9, pp. 614-618. November 2000					
	DQ	Wright et al., "The human protanoid DP receptor stimulates mucin secretion in LS174T cells", British Journal of Pharmacology, 131, 1537-1545, (2000)					
-	DR	Narumiya et al., "Protanoid Receptors: Structures, Properties, and Functions", Physiological Reviews, Vol. 79, No. 4, 1193-1226, October 1999					
	DS	Breider et al,. "Troglitazone-Induced Heart and Adipose Tissue Cell Proliferation in Mice, Toxicology Pathology, Vol. 27, No. 5, pp. 545-552, 1999					
	DT	Crider et al., "Prostaglandin DP receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EBTr) cells: pharmacological characterization using agonists and antagonists", British Journal of Pharmacology, 127, 204-210 (1999)					

Examiner Signature	Date Considered					
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with						
next communication to applicant						

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00216-654001	Application No. 10/721,118
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Cheng Hwang et al.	
		Filing Date November 25, 2003	Group Art Unit 1615

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.			
Initial	ID	Document		
	EA	Botchkarev et al., "A New Role for Neurotrophin-3", <i>American Journal of Pathology</i> , Volume 153, pp. 785-799, 1998.		
	EB	Botchkarev et al., "Neurotrophin-3 Involvement in the Regulation of Hair Follicle Morphogenesis", The Journal of Investigative Dermatology, Volume 111, No. 2, pp. 279-285, 1998.		
	EC	Wright et al., "Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist", British Journal of Pharmacology, 123, 1317-1324 (1998)		
	ED	Robert R. Henry, "Thiazolidinediones", Current Therapies for Diabetics, Vol. 26, No. 3, pp.553-573, September 1997		
	EE	Hoffmann et al., "Interleukin-1 β-Induced Inhibition of Hair Growth In Vitro Is Mediated by Cyclic AMP", The Journal of Investigative Dermatology, Volume 108, pp. 40-42, 1997.		
	EF	Messenger, Andrew G., "The Control of Hair Growth: An Overview", <i>The Journal of Investigative Dermatology</i> , Volume 101, No. 1, pp. 4s-9s, 1993.		
	EG	Weinberg et al., "Reconstitution of Hair Follicle Development In Vitro: Determination of Follicle Formation, Hair Growth, and Hair Quality by Dermal Cells", The Journal of Investigative Dermatology, Volume 100, pp. 229-236, 1993.		
	EH	Alvarez et al., "Stimulation of Prostaglandi D₂ Receptors on Human Platelets by Analogs of Prostacyclin", Prostaglandins, Vol. 42, No. 2, pp. 105-119, August 1991		
Geissler et al., "Thiazolidine-Diones Bi Tyrosine Protein Kinase Inhibitors", Th 22255-22261 December 25, 1990 Heinz-Thierauch et al., "ZK 110 841 - Prostaglandins in Clinical Research: C		Geissler et al., "Thiazolidine-Diones Biochemical and Biological Activity of a Novel Class of Tyrosine Protein Kinase Inhibitors", The Journal of Biological Chemistry, Vol. 265, No. 36, pp.		
		Heinz-Thierauch et al., "ZK 110 841 - A Selective and Potent Prostaglandin D ₂ Analogue", Prostaglandins in Clinical Research: Cardiovascular System, pp. 597-601, 1989		
	EK	Hirata et al., "Occurrence of 9-Deoxy- Δ^9 , Δ^{12} -13,14-dihydroprostaglandin D^2 in Human Urine, The Journal of Biological Chemistry, Vol. 263, No. 32, pp. 16619-16625, November 15, 1988		
	EL	Heinz-Thierauch et al., "Stable 9β- or 11α-Halogen-15-Cyclomethyl -Prostaglandins with High Affinity to the PGD ₂ -Receptor", Prostaglandins, Vol. 35, No. 6, pp. 855-868, June 1988		
	EM	Ebling, F. John G., "The Biology of Hair", <i>Dermatologic Clinics</i> , Volume 5, No. 3, pp. 467-481, 1987.		
	EN	Hattori et al., "Biochemical Analysis of Hair Growth From the Aspects of Aging and Enzyme Activities", <i>The Journal of Dermatology</i> , Volume 10, pp. 45-54, 1983.		
	EO	Bundy et al., "Synthesis and Platelet Aggregation Inhibiting Activity of Prostaglandin D Analogues", J. Med. Chem., 26, pp. 790-799, 1983		
	EP	Town et al., "Pharmacological and Cardiovascular Properties of a Hydantoin Derivative, BW 245 C, with High Affinity and Selectivity for PGD ₂ Receptors", Prostaglandins, Vol. 25, No. 1, pp. 13-28, January 1983		
	EQ	Caldwell et al., "Heterocyclic Prostaglandin Analogues. Part 2. Hydantoins and Other Imidazole Analogues", J. Chemical Society, Vol. 1, pp. 495-505, 1980		
	ER	Sato, Yoshio, "The Hair Cycle and Its Control Mechanism", pp. 3-13, 1976		
	ES	Adachi et al., "Human Hair Follicles: Metabolism and Control Mechanisms", Journal of the Society of Cosmetic Chemists, Volume 21, Number 13, pp. 901-924, 1970.		

Examiner Signature	Date Considered	
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		